ArticleCureus2025
Radiotherapy for Hypopharyngeal Carcinoma: Analysis of Multi-institutional Data From Over 170 Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim To examine the efficacy of radiotherapy (RT) for treating hypopharyngeal carcinoma (HPC), including the impact of transitioning from conventional three-dimensional conformal radiotherapy (3DCRT) to intensity-modulated radiotherapy (IMRT). Materials and methods We examined the outcomes of 171 patients with Stage I-IV HPC who were treated with definitive RT (87 with 3DCRT and 84 with IMRT) at three institutions between 2008 and 2024. The primary endpoint was overall survival (OS), and the secondary endpoints were local control (LC), locoregional control (LRC), progression-free survival (PFS), and toxicity. Results With a median follow-up time of 32 months (range, 2-127 months), the 2-year (2y) and 5-year (5y) OS rates were 83.9% (95% confidence interval [CI]: 77.1-88.9%) and 69.0% (95% CI: 58.8-77.1%), respectively. The 2y LC (5y), LRC, and PFS were 81.1% (74.1%), 78.1% (71.3%), and 64.3% (52.3%), respectively. The advanced T category was a statistically significant predictor of poor prognosis for both LC and LRC in the univariate analysis. Multivariate analyses found that N category (N0-1 vs. N2-3, hazard ratio = 1.7, 95% CI: 1.16-2.5, P = 0.0068) was a statistically significant predictor of OS. Five patients (2.8%) experienced late toxicities of grade ≥ 3. The transition from conventional 3DCRT to IMRT did not significantly alter the tumor control or toxicity profiles. Conclusion Definitive RT achieved favorable OS, LC, LRC, and PFS in patients with HPC, with acceptable toxicity. IMRT provides comparable efficacy and safety to 3DCRT for the treatment of HPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.